Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
Author:
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-5491.2012.03745.x/fullpdf
Reference18 articles.
1. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors;Verspohl;Pharmacol Ther,2009
2. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study;Moretto;Clin Ther,2008
3. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy, significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes;Vilsboll;Diabetes Care,2007
4. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes;Aschner;Diabetes Obes Metab,2010
5. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes;Kim;Diabetes Care,2007
Cited by 85 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression;Diabetes, Obesity and Metabolism;2024-03-20
2. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression;2024-01-30
3. Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment;Diabetes, Metabolic Syndrome and Obesity;2024-01
4. The Types and Applications of Peptibodies;International Journal of Peptide Research and Therapeutics;2023-12-27
5. The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials;European Journal of Clinical Investigation;2023-11-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3